**Regular Article**

**Astragaloside IV Regulates the PI3K/Akt/HO-1 Signaling Pathway and Inhibits H9c2 Cardiomyocyte Injury Induced by Hypoxia–Reoxygenation**

Ping Yang, Qing Xia, Lipeng Yao, and Xiuchun Chang

Ningbo College of Health Sciences; Ningbo 315100, China: and The Affiliated Hospital of Medical School of Ningbo University; Ningbo 315020, China.

Received November 1, 2018; accepted January 20, 2019; advance publication released online March 13, 2019

Astragaloside IV (AS-IV) is one of the main pharmacologically active compounds found in *Astragalus membranaceus*. AS-IV has protective effects against ischemia–reperfusion injury (IRI), but its mechanism of action has not yet been determined. This study aims to investigate the effect of AS-IV on IRI and its effect on the phosphatidylinositol 3-kinase (PI3K)/Akt/heme oxygenase (HO-1) signaling pathway through *in vitro* experiments. Firstly, a cell culture model of myocardiocyte hypoxia–reoxygenation (H/R) injury was replicated. After AS-IV treatment, cell viability, reactive oxygen species (ROS) levels, as well as the content or activity of the cellular factors lactate dehydrogenase (LDH), superoxide dismutase (SOD), malondialdehyde (MDA), interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-α), were measured to evaluate the effect of treatment with AS-IV. The effect of AS-IV on HO-1 protein expression and nuclear factor E2-related factor 2 (Nrf2) and Bach1 protein expression was determined by Western blotting. Finally, a reversal of the effect of AS-IV treatment was observed following co-incubation with a PI3K inhibitor. Our results show that AS-IV has good protective effect on H/R injury and has anti-oxidative stress and anti-inflammatory effects. It can regulate the expression of Nrf2 and Bach1 proteins in the nucleus and promote the expression of HO-1 protein, while a PI3K inhibitor can partially reverse the above effects. This study suggests that the PI3K/Akt/HO-1 signaling pathway may be a key signaling pathway for the anti-IRI effect of AS-IV.

**Key words** astragaloside IV; H9c2 cardiomyocyte; hypoxia–reoxygenation injury; heme oxygenase (HO-1); phosphatidylinositol 3-kinase–Akt pathway

**INTRODUCTION**

The traditional Chinese medicine consisting of the root of *Astragalus membranaceus* BUNGE has been widely used in the treatment of various diseases for several thousands of years. Astragaloside-IV (AS-IV) is one of the main pharmacologically active substances of *A. membranaceus* BUNGE. Studies have confirmed that AS-IV has protective effect against cardiovascular disease, ischemic encephalopathy, diabetes, liver fibrosis, and other diseases. Its mechanism of action involves anti-inflammatory, anti-oxidative, anti-fibrotic, and immunoregulatory actions. In recent years, *in vitro* and *in vivo* studies have shown that AS-IV is protective against myocardial ischemia–reperfusion injury (IRI) and its mechanism of action is mainly related to anti-oxidative stress and anti-inflammatory pathways. However, the specific target molecules and signaling pathways involved still await further study. Heme oxygenase (HO-1) is recognized as an important anti-oxidative stress and tissue protective enzyme that produces CO and biliverdin, and can also induce multiple anti-oxidative and anti-inflammatory signaling pathways, which significantly reduce cellular damage and protect organ function. As a novel protective factor in myocardiocytes, HO-1 plays an important role in mitigating damage due to myocardial IRI through the anti-inflammatory, anti-oxidative stress, anti-apoptotic, and anti-arrhythmic effects of its products. In this study, we further studied the mechanism through which AS-IV induces HO-1 expression and its related signaling pathways on an *in vitro* model of myocardial IRI.

**MATERIALS AND METHODS**

**Main Materials** The H9c2 rat cardiomyocyte cell line was purchased from The Institute of Life Sciences cell bank (Shanghai, China). AS-IV (Lot No. H-013-170614), purity 99.06%, was purchased from Herbpurify Co., Ltd. (Chengdu, China), and its molecular structure is shown in Fig. 1. AS-IV (5 g) was stored at the Institute of Biochemistry and Molecular Biology of Ningbo University to permit future reference and verification. Dulbecco’s modified Eagle’s medium (DMEM) was purchased from Gibco Co. (Grand Island, NY, U.S.A.). Fetal bovine serum (FBS) was purchased from Hyclone Co. (Logan, UT, U.S.A.). Cell Counting Kit-8 (CCK-8) was purchased from.

![Fig. 1. Chemical Structure of AS-IV](image)

Molecular formula, C_{41}H_{68}O_{14}, molecular weight, 784.9702 g/mol.
Lianke Biology Technology Co., Ltd. (Hangzhou, China). Reactive oxygen species (ROS), lactate dehydrogenase (LDH), superoxide dismutase (SOD), and malondialdehyde (MDA) kits were purchased from Institute of Bioengineering (Nanjing, China). Tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) enzyme-linked immunosorbent assay (ELISA) kits were purchased from USCN Co., Ltd. (Wuhan, China). Cell lysis buffer for Western and nuclear protein extraction kit, BCA protein quantification kit, and ECL luminescence kit for Western blotting were purchased from Beyotime Biotechnology Co. (Shanghai, China). Phosphatidylinositol 3-kinase (PI3K), p-Akt, Akt, HO-1, nuclear factor E2-related factor 2 (Nrf2), Bach1, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and HistoneH3 rabbit anti-rat polyclonal antibodies were purchased from Proteintech Co. (Shanghai, China). Cobalt protoporphyrin (CoPP, HO-lagondist) and zinc(II) protoporphyrin IX complex (ZnPP, HO-1 inhibitor) were purchased from Sigma-Aldrich Co. (St. Louis, MO, U.S.A.). PI3K inhibitor LY294002 was purchased from Selleck Co. (Houston, TX, U.S.A.).

Cell Culture and Hypoxia–Reoxygenation (H/R) Model Replication H9c2 cardiomyocytes were seeded in DMEM containing 10% FBS, placed in a constant temperature incubator at 37°C under 5% CO₂. Cells were subcultured based on their density and logarithmic growth phase (approximately 80% confluent) cells were used for experiments. After optimizing experimental conditions, the H9c2 H/R model was determined: the cells were cultured for 24 h, then cultured for 12 h under hypoxia and hypoglycemia, followed by reoxygenation in media containing optimal glucose for 8 h.

Toxicity of ASIV on Normal H9c2 Cells H9c2 cells in logarithmic growth phase were divided into the control group, H/R model group, and four AS-IV treatment groups (0.1, 1, 10, 100 µM). After incubating for 20 h, cell viability was measured using CCK-8. Cell viability (%) = (test well OD − blank well OD)/(control well OD − blank well OD) × 100.

Determination of AS-IV Effective Concentration H9c2 cells in logarithmic growth phase were divided into the control group, H/R model group, and four AS-IV treatment groups (0.1, 1, 10, 100 µM). During H/R model establishment, the cells were incubated in the presence of AS-IV for 20 h, cell viability was measured using CCK-8, and the LDH content of the cell supernatant was measured using the LDH kit.

Cell Grouping and Treatment Methods Logarithmic growth phase cells were randomly divided into the following groups: control group (cultured under normal conditions for 20 h), H/R model group, and four AS-IV treatment groups (0.1, 1, 10, 100 µM). During H/R model establishment, the cells were incubated for 20 h with H/R conditions, and the cell viability was measured using CCK-8, and the LDH content of the cell supernatant was measured using the LDH kit.

Statistical Analysis The data were analyzed and processed using SPSS19.0. Data were expressed as mean ± standard deviation (S.D.) (x ± s). One-way ANOVA was used for comparison between groups. The Least-Significant Difference method was used for further comparison between the two groups. p < 0.05 indicates statistically significant differences.

RESULTS

AS-IV Reduces Cytotoxicity to H9c2 Cells Induced by H/R Injury The CCK-8 assay demonstrates cell viability. The range of concentrations of AS-IV used in this experiment (0.1–100 µM) have no significant effect on the viability of normal cultured H9c2 cells (p > 0.05) (Fig. 2A). Compared to the control group, the viability of the H/R group decreased significantly (p < 0.01). Compared to the H/R group, the AS-IV 10 and 100 µM treatment groups showed significantly increased cell viability (p < 0.01), while the AS-IV 0.1 and 1 µM treatment groups showed no significant effect (Fig. 2B).
2B). The LDH assay indicates that LDH activity in the H/R group was significantly higher than that in the control group ($p < 0.01$). Compared with the H/R group, treatment with 10 and 100 µM AS-IV significantly decreased the LDH activity level ($p < 0.01$). However, AS-IV administered at 0.1 and 1 µM had no significant effect on LDH activity ($p > 0.05$) (Fig. 2C). These results indicate that the viability of H/R model cells is significantly decreased, and that H/R injury-induced cytotoxicity is significantly increased. AS-IV treatment at concentrations of 10 and 100 µM significantly increases cell viability and reduces cytotoxicity. As results using 100 µM was superior to those obtained with 10 µM AS-IV, subsequent experiments were performed with AS-IV100 µM.

AS-IV Alleviates Oxidative Damage of H9c2 Cells Induced by H/R Injury

Experimental results show that when compared to the control group, ROS level and MDA activity increased significantly in the H/R group, while SOD activity decreased significantly ($p < 0.01$). Compared with the H/R group, ROS level and MDA activity decreased significantly in the AS-IV and CoPP treatment groups, while SOD activity increased significantly ($p < 0.01$). Compared with the AS-IV group, ROS level and MDA activity increased significantly in the AS-IV + ZnPP treatment group, while SOD activity decreased significantly ($p < 0.01$) (Figs. 3A, B). These findings indicate that AS-IV and CoPP have significant anti-oxidative stress effects, and ZnPP can partially reverse the anti-oxida-
tive stress effects of AS-IV.

**AS-IV Reduces the Inflammatory Response of H9c2 Cells Induced by H/R Injury**  
Experimental results show that compared with the control group, the levels of IL-6 and TNF-α secreted by cells in the H/R group were significantly increased ($p < 0.01$). Compared to the H/R group, the cells in the AS-IV and CoPP treatment groups secreted significantly less IL-6 and TNF-α ($p < 0.01$). Compared with the AS-IV group, IL-6 and TNF-α secretion increased significantly in the AS-IV + ZnPP treatment group ($p < 0.01$) (Figs. 4A, B). This indicates that AS-IV and CoPP have significant anti-inflammatory effects and that ZnPP can partially reverse the anti-inflammatory effects of AS-IV.

**Effect of AS-IV on Activation of PI3K/Akt/HO-1 Signaling Pathway**  
Western blotting showed that the expression of PI3K and p-Akt in the H/R group was significantly lower than that in the control group ($p < 0.01$). Compared with the H/R group, the expression of PI3K and p-Akt in the AS-IV group increased significantly ($p < 0.01$). Compared with the AS-IV group, PI3K and p-Akt expression in the PI3K-specific inhibitor LY294002 group decreased significantly ($p < 0.01$) (Figs. 5A, D, G). Compared with the control group, the expression of HO-1 in the H/R group increased significantly ($p < 0.01$). Compared with the H/R group, the expression of HO-1 in the AS-IV group increased significantly ($p < 0.01$). In comparison, the expression of HO-1 in the LY294002 group decreased significantly ($p < 0.01$) (Figs. 5B, G). The results suggest that AS-IV promotes HO-1 protein expression, and PI3K-specific inhibitors partially reverse this effect. In addition, AS-IV had no influence to the basal expression of PI3K,
p-Akt, HO-1, Nrf2 and Bach1 (p > 0.05) (Fig. S1 available online).

Western blotting also showed that the expression of Nrf2 in the H/R group was significantly higher than that in the control group (p < 0.01). Compared with the H/R group, the expression of Nrf2 in the AS-IV group increased significantly (p < 0.01). Compared with the AS-IV group, the expression of Nrf2 in the LY294002 group decreased significantly (p < 0.01) (Figs. 5E, H). Compared with the control group, the expression of Bach1 increased significantly in the H/R group (p < 0.01). Compared with the H/R group, the expression of Bach1 decreased significantly in the AS-IV group (p < 0.01). Compared with the AS-IV group, the expression of Bach1 increased significantly in the LY294002 group (p < 0.01) (Figs. 5F, H). The results suggest that AS-IV can significantly increase nuclear Nrf2 expression, while decreasing nuclear Bach1 expression, and PI3K specific inhibitors can partially reverse this effect.

DISCUSSION

Reducing myocardial IRI has been a primary focus of researchers and clinicians. It is generally believed that the occurrence and development of IRI is due to a cascade of multi-factor interactions, which are mutually causal and mutually influential, and ultimately lead to the apoptosis and death of cardiomyocytes. Free radical damage and inflammatory responses are believed to play key roles in myocardial IRI. In recent years, the role of HO-1 in myocardial IRI has received a great deal of attention. Numerous studies have shown that HO-1 and its metabolites are widely involved in anti-oxidative stress, anti-inflammatory damage, anti-cell proliferation, anti-apoptosis, inhibition of platelet aggregation, regulation of vascular tone, and intracellular signaling and play a very important role in cardiovascular diseases. HO-1 appears to be particularly closely related to myocardial IRI, as the expression of HO-1 is significantly increased in the early stage of myocardial IRI. Over-expression of the HO-1 gene in cardiomyocytes or increased myocardial HO-1 expression via gene therapy or drug therapy can significantly reduce the infarct surface area due to ischemia during IRI and significantly improve myocardial function. Mice deficient in the HO-1 gene showed more severe IRI. In this study, by replicating the myocardial H/R cell culture model, we were able to separately administer HO-1 agonists and inhibitors. The study also confirmed that HO-1 can significantly inhibit the expression of inflammatory factors and increase the level of anti-oxidants, indicating that HO-1 is protective against myocardial H/R injury via protection against oxidative stress and inhibition of inflammation.

The above results suggest that by highly expressing HO-1 levels, myocardial IRI can be attenuated to some extent. Both in vitro and in vivo experiments have confirmed that AS-IV has significant protective effects against myocardial IRI, but its mechanism of action needs to be further explored. In this study, the mechanism of action of AS-IV was further studied using an in vitro myocardial H/R model. The results show that after treatment with AS-IV, the expression of HO-1 is significantly increased, the secretion of cytokines is significantly reduced, and the anti-oxidative stress capacity of cells is enhanced. A HO-1 inhibitor partially reversed the above effects, suggesting that induction of HO-1 was the source of the above changes. The expression of HO-1 is one of the mechanisms of action by which AS-IV protects against myocardial H/R injury. But what is the signaling pathway through which AS-IV induces HO-1?

Studies have shown that the regulation of HO-1 gene expression occurs mainly at the transcriptional level. Nuclear factor E2-related factor 2 (Nrf2) is an important transcriptional regulator of anti-oxidative stress. When cardiomyocytes are under oxidative stress, Nrf2 is rapidly phosphorylated, dissociates, activates, and translocates to the nucleus, where it binds to the anti-oxidative stress response element (ARE) to promote the expression of anti-oxidant proteins such as HO-1 and SOD to combat oxidative stress caused by ischemia and hypoxia. Tanaka et al. found that deletion of the Nrf2 gene results in a significant decrease in the expression of various baseline and inducible anti-oxidant genes, including HO-1, and an overall increase in oxidative damage. On the other hand, gene regulation of HO-1 is also negatively regulated by some Nrf2 repressors, such as BTB-CNC allogeneic 1 (BTB and CNC homology 1, Bach1), and deletion of the Bach1 gene can lead to increased expression of HO-1. The mechanism by which Bach1 and Nrf2 antagonize the expression of anti-oxidant genes may be related to the competitive binding of ARE sequences in the nucleus. Oxidative stress phosphorylates Bach1 tyrosine 486, allowing for rapid nuclear exit and for Nrf2 to bind to available AREs, resulting in the production of anti-oxidant enzymes.

The above experimental results suggest that the dynamic equilibrium relationship between Nrf2 and Bach1 in the nucleus affects the transcription of anti-oxidant enzymes such as HO-1.

Phosphatidylinositol 3-kinase (PI3K) is an intracellular phosphatidylinositol kinase that is a second messenger located on the plasma membrane Akt is a key downstream gene in the PI3K/Akt pathway. Akt induces phosphorylation of serine and threonine residues and activates or inhibits downstream target gene expression. The PI3K/Akt signaling pathway is essential for heart and vascular health. As an important part of the body’s protective mechanism, the PI3K/Akt pathway plays a major role in controlling cell growth, survival, proliferation, and migration, and improves overall function in IRI through activating Akt. PI3K may affect the expression of HO-1 by regulating the balance of Nrf2 and Bach1. Sun et al. showed that inhibition of the PI3K/Akt pathway significantly reduces HO-1 protein expression, thereby attenuating the protective effects of HO-1 on cardiomyocytes. Joung et al. stimulated HepG2 cells with capsaicin to activate the PI3K/Akt pathway, increasing the nuclear translocation of Nrf2 and the transcriptional activity of AREs, and thereby increasing the expression of HO-1 in cells. Other studies have shown that chlorophyllin induces nuclear translocation of Nrf2 via activation of the PI3K pathway, up-regulating HO-1 expression in human umbilical vein endothelial cells in a time- and dose-dependent manner. These findings strongly confirm that PI3K/Akt upregulates the Nrf2–ARE pathway and mediates HO-1 expression. There are fewer reports on whether PI3K-mediated HO-1 expression is simultaneously achieved by down-regulating Bach1 activity. In an experiment on Jurkat tumor cells, the PI3K signaling pathway was shown to activate Nrf2 and inhibit Bach1 activity, thereby regulating HO-1 expression.
However, there are only a few studies on whether PI3K/Akt signaling pathway regulates HO-1 in myocardial IRI. A recent study showed that, a Chinese herbal medicine extract (TFFC) protects against myocardial injury and enhances cellular antioxidant defense capacity by inducing the phosphorylation of Akt, which subsequently activates the Nrf2/HO-1 signaling pathway. In addition, two studies showed that AS-IV has protective effects on the cardiovascular system by regulating the PI3K/Akt signaling pathway. However, whether AS-IV further induces HO-1 expression by regulating the PI3K/Akt signaling pathway and its downstream effectors remains unclear. The results of this study show that the effect of AS-IV on myocardial H/R injury can significantly increase the expression of PI3K and p-Akt in cells, thereby increasing the nuclear expression of Nrf2 and decreasing the nuclear expression of Bach1, and further increased the expression of HO-1 protein, while a PI3K-specific inhibitor can partially reverse the above effects. These results suggest that AS-IV may affect the nuclear translocation of Nrf2 and Bach1 by activating the PI3K/Akt signaling pathway thereby regulating the expression of HO-1. Therefore, this study confirms that the PI3K/Akt/HO-1 signaling pathway is a key signaling pathway for the anti-myocardial H/R injury of AS-IV.

Acknowledgments This study was supported by the Natural Science Foundation of Ningbo municipality (No. 2017A610260).

Conflict of Interest The authors declare no conflict of interest.

Supplementary Materials The online version of this article contains supplementary materials.

REFERENCES


